TenSixty Biosciences
TenSixty BioSciences innovates small molecule therapeutics through high throughput experiments.
Founded
2021TenSixty BioSciences innovates small molecule therapeutics through high throughput experiments.
Founded with the mission to revolutionize cancer treatment, TenSixty Biosciences leverages cutting-edge genomics, proteomics, machine learning, and cancer biology to innovate small molecule therapeutics. The company focuses on identifying novel and precise antibody targets on cancer cells through high throughput experiments and advanced AI technologies. Their core vision is to create an innovative atlas of these targets, enabling groundbreaking discoveries in cancer therapy.
Notable figures affiliated with TenSixty Biosciences include leading experts in genomics and proteomics, though specific names are not provided. The company has attracted significant attention from investors interested in the intersection of biotechnology and artificial intelligence. Key achievements include the development of a sophisticated AI-driven platform for target identification, which has the potential to significantly impact cancer treatment outcomes. Overall, TenSixty Biosciences is making substantial strides in the biotech industry by pushing the boundaries of cancer research and therapeutic development.
Companies similar to TenSixty Biosciences include GV20 Therapeutics, Ten63 Therapeutics, BigHat Biosciences and Gordion Bioscience.
TenSixty Biosciences was founded in 2021.
TenSixty Biosciences' headquarters is located in Cambridge, MA, US.
As of May 9, 2023, TenSixty Biosciences has disclosed funding of $7.2M (USD). Undisclosed round amounts are excluded.
TenSixty Biosciences has 50 employees as of Feb 5, 2024.
Gordion Bioscience
gordion.bio
